tiprankstipranks
aTyr Pharma (DE:471A)
FRANKFURT:471A
Germany Market
471A
aTyr Pharma
RESEARCH TOOLSreports

aTyr Pharma (471A) Stock Forecast & Price Target

13 Followers
See the Price Targets and Ratings of:

471A Analyst Ratings

Moderate Buy
6Ratings
Moderate Buy
2 Buy
4 Hold
0 Sell
Based on 6 analysts giving stock ratings to
aTyr
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

471A Stock 12 Month Forecast

Average Price Target

€2.71
▲(697.68% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for aTyr Pharma in the last 3 months. The average price target is €2.71 with a high forecast of €6.08 and a low forecast of €0.87. The average price target represents a 697.68% change from the last price of €0.34.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","3":"€3","5":"€5","7":"€7","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.0751601399999995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.7121250624999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.86788002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.87</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1,3,5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.7627046261538462,1.2054092523076922,1.6481138784615383,2.090818504615384,2.5335231307692303,2.9762277569230764,3.4189323830769225,3.8616370092307686,4.304341635384615,4.747046261538461,5.189750887692307,5.632455513846153,{"y":6.0751601399999995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.5040096201923077,0.6880192403846154,0.8720288605769231,1.0560384807692307,1.2400481009615385,1.424057721153846,1.608067341346154,1.7920769615384615,1.9760865817307691,2.1600962019230767,2.3441058221153845,2.528115442307692,{"y":2.7121250624999997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.32,0.3621446169230769,0.40428923384615384,0.4464338507692308,0.4885784676923077,0.5307230846153846,0.5728677015384616,0.6150123184615385,0.6571569353846154,0.6993015523076923,0.7414461692307692,0.7835907861538461,0.8257354030769231,{"y":0.86788002,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.61,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.755,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.575,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.6,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.615,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.575,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.552,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.356,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.419,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€6.08Average Price Target€2.71Lowest Price Target€0.87
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:471A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€6.08
Buy
1686.81%
Upside
Reiterated
07/16/26
aTyr Pharma (ATYR) Receives a Buy from Piper Sandler
JonesTrading Analyst forecast on DE:471A
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Reiterated
07/16/26
Analysts Conflicted on These Healthcare Names: aTyr Pharma (NASDAQ: ATYR), Kymera Therapeutics (NASDAQ: KYMR) and Cannara Biotech (Other OTC: LOVFF)
H.C. Wainwright Analyst forecast on DE:471A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
07/16/26
Joseph Pantginis Reiterates Hold as Efzofitimod Shifts to Restrictive Lung Phenotype After Mixed Phase 3 EFZO-FIT Results
Freedom Capital Markets Analyst forecast on DE:471A
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
€0.87→€3.04
Buy
793.41%
Upside
Upgraded
05/20/26
aTyr Pharma upgraded to Buy from Hold at Freedom BrokeraTyr Pharma upgraded to Buy from Hold at Freedom Broker
Wells Fargo Analyst forecast on DE:471A
Derek Archila
Wells Fargo
Wells Fargo
€0.87
Hold
155.26%
Upside
Assigned
05/18/26
Wells Fargo Sticks to Their Hold Rating for aTyr Pharma (ATYR)
RBC Capital Analyst forecast on DE:471A
Brian Abrahams
RBC Capital
RBC Capital
€0.87
Hold
155.26%
Upside
Reiterated
05/15/26
RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)
Jefferies Analyst forecast on DE:471A
Faisal Khurshid
Jefferies
Jefferies
―
Hold
―
Reiterated
09/30/25
Leerink Partners Remains a Hold on aTyr Pharma (ATYR)
Lucid Capital Analyst forecast on DE:471A
Dev Prasad
Lucid Capital
Lucid Capital
€9.55→€0.87
Hold
155.26%
Upside
Downgraded
09/15/25
aTyr Pharma downgraded to Neutral from Buy at Lucid CapitalaTyr Pharma downgraded to Neutral from Buy at Lucid Capital
Cantor Fitzgerald Analyst forecast on DE:471A
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
09/15/25
aTyr Pharma (ATYR) Gets a Buy from Cantor Fitzgerald
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on DE:471A
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€6.08
Buy
1686.81%
Upside
Reiterated
07/16/26
aTyr Pharma (ATYR) Receives a Buy from Piper Sandler
JonesTrading Analyst forecast on DE:471A
Boris Peaker
JonesTrading
JonesTrading
―
Hold
―
Reiterated
07/16/26
Analysts Conflicted on These Healthcare Names: aTyr Pharma (NASDAQ: ATYR), Kymera Therapeutics (NASDAQ: KYMR) and Cannara Biotech (Other OTC: LOVFF)
H.C. Wainwright Analyst forecast on DE:471A
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Reiterated
07/16/26
Joseph Pantginis Reiterates Hold as Efzofitimod Shifts to Restrictive Lung Phenotype After Mixed Phase 3 EFZO-FIT Results
Freedom Capital Markets Analyst forecast on DE:471A
Ilya Zubkov
Freedom Capital Markets
Freedom Capital Markets
€0.87→€3.04
Buy
793.41%
Upside
Upgraded
05/20/26
aTyr Pharma upgraded to Buy from Hold at Freedom BrokeraTyr Pharma upgraded to Buy from Hold at Freedom Broker
Wells Fargo Analyst forecast on DE:471A
Derek Archila
Wells Fargo
Wells Fargo
€0.87
Hold
155.26%
Upside
Assigned
05/18/26
Wells Fargo Sticks to Their Hold Rating for aTyr Pharma (ATYR)
RBC Capital Analyst forecast on DE:471A
Brian Abrahams
RBC Capital
RBC Capital
€0.87
Hold
155.26%
Upside
Reiterated
05/15/26
RBC Capital Sticks to Its Hold Rating for aTyr Pharma (ATYR)
Jefferies Analyst forecast on DE:471A
Faisal Khurshid
Jefferies
Jefferies
―
Hold
―
Reiterated
09/30/25
Leerink Partners Remains a Hold on aTyr Pharma (ATYR)
Lucid Capital Analyst forecast on DE:471A
Dev Prasad
Lucid Capital
Lucid Capital
€9.55→€0.87
Hold
155.26%
Upside
Downgraded
09/15/25
aTyr Pharma downgraded to Neutral from Buy at Lucid CapitalaTyr Pharma downgraded to Neutral from Buy at Lucid Capital
Cantor Fitzgerald Analyst forecast on DE:471A
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
09/15/25
aTyr Pharma (ATYR) Gets a Buy from Cantor Fitzgerald
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
TNYATenaya Therapeutics
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering aTyr Pharma

3 Months
Yasmeen RahimiPiper Sandler
Success Rate
8/15 ratings generated profit
53%
Average Return
+8.79%
Copying Yasmeen Rahimi's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +8.79% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
5/15 ratings generated profit
33%
Average Return
-8.25%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -8.25% per trade.
2 Years
Yasmeen RahimiPiper Sandler
Success Rate
0/15 ratings generated profit
0%
Average Return
-55.07%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -55.07% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

471A Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
3
2
4
2
Buy
0
0
0
0
0
Hold
5
9
7
9
4
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
12
9
13
6
In the current month, 471A has received 2 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 471A average Analyst price target in the past 3 months is 2.71.
Each month's total comprises the sum of three months' worth of ratings.

471A Financial Forecast

471A Earnings Forecast

Next quarter’s earnings estimate for 471A is -€0.11 with a range of -€0.14 to -€0.09. The previous quarter’s EPS was -€0.10. 471A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.74% of the time in the same period. In the last calendar year 471A has Performed in-line its overall industry.
Next quarter’s earnings estimate for 471A is -€0.11 with a range of -€0.14 to -€0.09. The previous quarter’s EPS was -€0.10. 471A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.74% of the time in the same period. In the last calendar year 471A has Performed in-line its overall industry.

471A Sales Forecast

Next quarter’s sales forecast for 471A is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 471A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 39.76% of the time in the same period. In the last calendar year 471A has Performed in-line its overall industry.
Next quarter’s sales forecast for 471A is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 471A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 39.76% of the time in the same period. In the last calendar year 471A has Performed in-line its overall industry.

471A Stock Forecast FAQ

What is DE:471A’s average 12-month price target, according to analysts?
Based on analyst ratings, aTyr Pharma’s 12-month average price target is 2.71.
    What is DE:471A’s upside potential, based on the analysts’ average price target?
    aTyr Pharma has 697.68% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is aTyr Pharma a Buy, Sell or Hold?
          aTyr Pharma has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 4 hold ratings and 0 sell ratings.
            What is aTyr Pharma’s share price target?
            The average share price target for aTyr Pharma is 2.71. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €6.08 ,and the lowest forecast is €0.87. The average share price target represents 697.68% Increase from the current price of €0.34.
              What do analysts say about aTyr Pharma?
              aTyr Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of aTyr Pharma?
                To buy shares of DE:471A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.